ADTX · Aditxt, Inc.
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions. Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
Cap structure and valuation
| Cap structure | |
|---|---|
| SP | $0.00 |
| SO | 0.8M |
| Options | 5.1M |
| Warrants | 0.0M |
| FD SO | 5.9M |
| MC | $0.0M |
| Cash | $0.3M |
| Total debt | $3.3M |
| EV | $3.1M |
| TTM Multiples | |
|---|---|
| EV / Revenue | 213.3x |
| EV / EBITDA | — |
| MC / Net Income | — |
| EV / FCF | — |
| MC / FCF | — |
| Ownership & coverage | |
|---|---|
| Institutional | 0.0% |
| Insiders | 0.1% |
| # Institutions | 1 |
| Analysts | 0 |
| Consensus | — |
| Avg target | — |
| Short % float | 34.5% |
| Days to cover | 0.00 |
MC = SP × FD SO. EV = MC + Debt − Cash. SP = previous yfinance close. Balance-sheet figures as of 2026-05-20. Multiples use TTM (sum of last 4 quarters); shown as "—" when the denominator is zero or negative, or when fewer than four quarters are reported — a partial sum is not a trailing twelve months. Ownership & coverage per Yahoo Finance as of 2026-07-13 — institutional % is 13F-based, so it can lag a quarter and exceed 100% on share-count timing. Short interest per FINRA bi-monthly reporting, as of 2026-06-14; the float denominator can be unreliable on tiny floats.
Financial statements
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Total Revenue | 0.01 | 0.00 | 0.00 | 0.00 |
| Revenue YoY % | 1094.4% | (86.6%) | (89.1%) | (97.7%) |
| Cost of Revenue | 0.01 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | (0.00) | 0.00 | (0.00) |
| Gross Profit YoY % | 909.9% | 100.0% | 100.0% | (100.0%) |
| Gross Margin % | 23.6% | (7.3%) | 2.1% | (0.1%) |
| SG&A | 3.32 | 4.12 | 2.47 | 5.39 |
| R&D | 1.05 | 0.55 | 0.67 | 0.76 |
| Operating Expense | 4.36 | 4.67 | 3.14 | 6.15 |
| Operating Income | (4.36) | (4.67) | (3.14) | (6.15) |
| Operating Income YoY % | 22.2% | 17.4% | 33.2% | (3.0%) |
| Operating Margin % | (35873.5%) | (1098725.6%) | (419870.3%) | (612788.3%) |
| EBITDA | (4.31) | (4.60) | (3.07) | (6.09) |
| EBITDA Margin % | (35479.7%) | (1083006.4%) | (410953.5%) | (606110.4%) |
| Interest Expense | 0.03 | 0.30 | 0.18 | 0.05 |
| Other Income / (Expense) | (11.80) | — | (20.89) | (1.20) |
| Pretax Income | (16.19) | (5.23) | (24.21) | (7.40) |
| Net Income | (16.19) | (5.23) | (24.21) | (7.40) |
| Net Income to Common | (15.95) | (6.09) | (24.05) | (7.26) |
| Net Margin % | (133145.8%) | (1230882.6%) | (3236319.4%) | (736619.3%) |
| Diluted EPS | -$790.49 | $451.34 | -$548.78 | -$3.45 |
| Basic EPS | -$790.49 | $451.34 | -$548.78 | -$3.45 |
| Diluted Avg Shares | 0.0 | — | 0.0 | 2.1 |
| Basic Avg Shares | 0.0 | — | 0.0 | 2.1 |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Total Revenue | 0.01 | 0.00 | 0.13 | 0.65 | 0.93 |
| Revenue YoY % | 348.7% | (97.6%) | (79.2%) | (30.9%) | — |
| Cost of Revenue | 0.01 | 0.00 | 0.63 | 0.76 | 0.77 |
| Gross Profit | 0.00 | 0.00 | (0.49) | (0.11) | 0.17 |
| Gross Profit YoY % | 964.2% | 100.1% | (342.0%) | (166.9%) | — |
| Gross Margin % | 19.9% | 8.4% | (368.3%) | (17.3%) | 17.9% |
| SG&A | 15.30 | 16.38 | 16.48 | 18.88 | 1.85 |
| R&D | 3.03 | 3.19 | 10.89 | 7.07 | 7.27 |
| Operating Expense | 18.33 | 19.57 | 27.37 | 25.95 | 25.65 |
| Operating Income | (18.32) | (19.57) | (27.86) | (26.06) | (25.48) |
| Operating Income YoY % | 6.4% | 29.8% | (6.9%) | (2.3%) | — |
| Operating Margin % | (127821.4%) | (612542.2%) | (20796.1%) | (4039.6%) | (2728.9%) |
| EBITDA | (18.08) | (19.30) | (27.25) | (25.63) | (25.05) |
| EBITDA Margin % | (126088.4%) | (604114.3%) | (20337.9%) | (3972.2%) | (2683.0%) |
| Interest Expense | 0.55 | 0.68 | 4.19 | 4.20 | 0.00 |
| Other Income / (Expense) | (34.15) | (22.54) | (2.97) | (2.13) | (2.17) |
| Pretax Income | (53.02) | (42.79) | (35.02) | (32.39) | (27.65) |
| Net Income | (53.02) | (42.79) | (35.02) | (32.39) | (27.65) |
| Net Income to Common | (53.34) | (43.10) | (40.35) | (32.70) | (27.65) |
| Net Margin % | (369864.5%) | (1339187.6%) | (26137.3%) | (5020.4%) | (2961.3%) |
| Diluted EPS | -$891.38 | -$1153.83 | -$22147415.22 | -$27038.26 | -$595.60 |
| Basic EPS | -$891.38 | -$1153.83 | -$22147415.22 | -$27038.26 | -$597.12 |
| Diluted Avg Shares | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Basic Avg Shares | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Cash & Equivalents | 0.27 | 3.20 | 0.16 | 0.32 |
| Receivables | 0.01 | — | 0.04 | 0.04 |
| Inventory | 0.13 | 0.01 | 0.01 | 0.01 |
| Other Current Assets | — | 0.62 | — | — |
| Total Current Assets | 0.85 | 3.82 | 0.42 | 0.43 |
| Net PPE | 0.81 | 0.88 | 1.35 | 1.41 |
| Operating Lease ROU | 0.97 | 1.20 | 0.70 | 0.89 |
| Goodwill | 0.54 | — | — | — |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term Investments | — | — | 7.05 | 27.54 |
| Other Assets | 10.74 | 10.61 | 2.27 | 2.41 |
| Total Assets | 13.91 | 16.52 | 11.80 | 32.69 |
| Accounts Payable | 7.73 | 7.34 | 10.36 | 9.68 |
| Current Lease Liabilities | 0.64 | 0.81 | 0.64 | 0.69 |
| Other Current Liabilities | 4.97 | 4.07 | 9.65 | 10.21 |
| Total Current Liabilities | 13.34 | 12.22 | 20.66 | 20.58 |
| Long-term Lease Liabilities | 0.29 | 0.34 | — | 0.11 |
| Other Liabilities | 35.45 | — | — | — |
| Total Liabilities | 49.08 | 12.56 | 20.66 | 20.70 |
| Retained Earnings | (225.76) | (209.81) | (205.11) | (181.06) |
| Total Equity | (35.17) | 3.95 | (8.86) | 11.99 |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 0.27 | 3.20 | 0.83 | 0.10 | 2.77 |
| Receivables | 0.01 | — | 0.04 | 0.41 | 0.53 |
| Inventory | 0.13 | 0.01 | 0.01 | 0.75 | 0.95 |
| Other Current Assets | — | 0.62 | 1.11 | 5.66 | — |
| Total Current Assets | 0.85 | 3.82 | 2.00 | 6.91 | 4.74 |
| Net PPE | 0.81 | 0.88 | 1.55 | 1.90 | 2.32 |
| Operating Lease ROU | 0.97 | 1.20 | 1.23 | 2.20 | 3.16 |
| Goodwill | 0.54 | — | — | — | — |
| Intangible Assets | 0.00 | 0.00 | 0.01 | 0.01 | 0.11 |
| Long-term Investments | — | — | — | 22.28 | — |
| Other Assets | 10.74 | 10.61 | 27.36 | 11.28 | — |
| Total Assets | 13.91 | 16.52 | 32.14 | 44.58 | 10.74 |
| Accounts Payable | 7.73 | 7.34 | 10.19 | 7.52 | — |
| Current Lease Liabilities | 0.64 | 0.81 | 0.68 | 1.00 | 1.09 |
| Other Current Liabilities | 4.97 | 4.07 | 12.53 | 17.37 | 2.56 |
| Total Current Liabilities | 13.34 | 12.22 | 23.41 | 25.89 | 3.64 |
| Long-term Lease Liabilities | 0.29 | 0.34 | 0.44 | 1.04 | 1.89 |
| Other Liabilities | 35.45 | — | — | 1.60 | — |
| Total Liabilities | 49.08 | 12.56 | 23.86 | 28.53 | 5.53 |
| Mezzanine Equity | — | — | 7.20 | — | — |
| Retained Earnings | (225.76) | (209.81) | (168.09) | (127.74) | (95.04) |
| Total Equity | (35.17) | 3.95 | 1.09 | 16.05 | 5.21 |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Net Income | (16.19) | (5.23) | (24.21) | (7.40) |
| D&A | 0.05 | 0.07 | 0.07 | 0.07 |
| Stock-Based Comp | — | 0.00 | 0.00 | — |
| Δ Working Cap & Other | 11.56 | (4.08) | 21.80 | 4.94 |
| Operating Cash Flow | (4.58) | (9.25) | (2.34) | (2.38) |
| CapEx | (0.01) | — | — | — |
| Investing Cash Flow | (0.01) | (0.01) | 0.00 | — |
| Other Financing | 1.66 | 12.29 | 2.18 | 4.66 |
| Financing Cash Flow | 1.66 | 12.29 | 2.18 | 4.66 |
| Free Cash Flow | (4.59) | — | — | — |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Net Income | (53.02) | (42.79) | (35.02) | (32.39) | (27.65) |
| D&A | 0.25 | 0.27 | 0.61 | 0.44 | 0.43 |
| Stock-Based Comp | — | 0.47 | 0.03 | 1.40 | 3.13 |
| Δ Working Cap & Other | 34.22 | 16.36 | 17.61 | 11.35 | 1.70 |
| Operating Cash Flow | (18.55) | (25.69) | (16.76) | (19.20) | (22.39) |
| CapEx | — | (0.01) | — | (0.01) | (0.37) |
| Other Investing | — | (2.42) | (5.00) | — | — |
| Investing Cash Flow | — | (2.44) | (5.00) | (0.01) | (0.24) |
| Stock Issuance | — | — | — | 0.51 | 17.23 |
| Other Financing | 20.80 | 30.49 | 22.50 | 16.04 | — |
| Financing Cash Flow | 20.80 | 30.49 | 22.50 | 16.55 | 17.53 |
| Free Cash Flow | — | (25.70) | — | (19.22) | (22.76) |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Current Ratio | 0.06 | 0.31 | 0.02 | 0.02 |
| Quick Ratio | 0.05 | 0.31 | 0.02 | 0.02 |
| Debt / Equity | -1.40 | 3.18 | -2.33 | 1.73 |
| EBITDA Margin % | (35479.7%) | (1083006.4%) | (410953.5%) | (606110.4%) |
| Working Capital | (12.49) | (8.40) | (20.24) | (20.15) |
| Net Debt | — | — | — | — |
| ROE % | 46.0% | (132.3%) | 273.2% | (61.7%) |
| ROA % | (116.4%) | (31.7%) | (205.2%) | (22.6%) |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Current Ratio | 0.06 | 0.31 | 0.09 | 0.27 | 1.30 |
| Quick Ratio | 0.05 | 0.31 | 0.08 | 0.24 | 1.04 |
| Debt / Equity | -1.40 | 3.18 | 21.86 | 1.78 | 1.06 |
| EBITDA Margin % | (126088.4%) | (604114.3%) | (20337.9%) | (3972.2%) | (2683.0%) |
| Working Capital | (12.49) | (8.40) | (21.41) | (18.98) | 1.10 |
| Net Debt | — | — | — | — | — |
| ROE % | 150.7% | (1082.2%) | (3208.7%) | (201.9%) | (531.1%) |
| ROA % | (381.3%) | (259.1%) | (108.9%) | (72.7%) | (257.6%) |
Insider activity (last 2 years)
| Date Filed | Reporter | Relationship | Trans. Date | Code | Shares | Price | Total Value |
|---|---|---|---|---|---|---|---|
| 2026-06-24 | HRT FINANCIAL LP | 10% Owner | 2026-06-22 | S | (5,120,480) | $0.02 | -$92,169 |
| 2026-06-24 | HRT FINANCIAL LP | 10% Owner | 2026-06-18 | P | 7,340,178 | $0.01 | $95,422 |
| 2026-06-18 | DRW Securities, LLC | 10% Owner | 2026-06-17 | S | (126,772) | $0.01 | -$1,001 |
| 2026-06-18 | HRT FINANCIAL LP | 10% Owner | 2026-06-16 | S | (3,132,480) | $0.01 | -$40,722 |
| 2026-06-17 | HRT FINANCIAL LP | 10% Owner | 2026-06-15 | P | (2,114,344) | $0.01 | -$29,601 |
| 2026-06-16 | HRT FINANCIAL LP | 10% Owner | 2026-06-12 | P | 4,252,767 | $0.02 | $68,044 |
| 2026-06-15 | BANK OF AMERICA CORP /DE/ | 10% Owner | 2026-06-11 | P | 1 | $0.02 | $0 |
| 2026-06-15 | BANK OF AMERICA CORP /DE/ | 10% Owner | 2026-06-11 | P | 1 | $0.02 | $0 |
| 2026-06-15 | BANK OF AMERICA CORP /DE/ | 10% Owner | 2026-06-11 | P | 1 | $0.01 | $0 |
| 2026-06-15 | BANK OF AMERICA CORP /DE/ | 10% Owner | 2026-06-11 | P | 1 | $0.01 | $0 |
| 2026-06-15 | BANK OF AMERICA CORP /DE/ | 10% Owner | 2026-06-11 | P | 3 | $0.01 | $0 |
| 2026-06-15 | BANK OF AMERICA CORP /DE/ | 10% Owner | 2026-06-11 | S | (15) | $0.01 | -$0 |
| 2026-06-12 | HRT FINANCIAL LP | 10% Owner | 2026-06-11 | S | (2,833,463) | $0.01 | -$39,668 |
| 2026-06-11 | HRT FINANCIAL LP | 10% Owner | 2026-06-10 | P | 725,330 | $0.02 | $13,781 |
| 2026-06-11 | HRT FINANCIAL LP | 10% Owner | 2026-06-09 | S | (878,659) | $0.03 | -$28,996 |
| 2026-06-11 | HRT FINANCIAL LP | 10% Owner | 2026-06-08 | P | 1,423,493 | $0.05 | $69,751 |
| 2026-06-10 | Gong Sandie | 10% Owner | 2026-06-09 | S | (100,000) | $0.07 | -$6,880 |
| 2026-06-08 | HRT FINANCIAL LP | 10% Owner | 2026-06-05 | S | (735,462) | $0.06 | -$45,599 |
| 2026-06-08 | HRT FINANCIAL LP | 10% Owner | 2026-06-04 | P | 843,622 | $0.08 | $64,115 |
| 2026-04-27 | HRT FINANCIAL LP | 10% Owner | 2026-04-24 | S | (29,404) | $0.28 | -$8,233 |
| 2026-04-27 | HRT FINANCIAL LP | 10% Owner | 2026-04-23 | S | (3,811) | $0.29 | -$1,105 |
| 2026-04-23 | HRT FINANCIAL LP | 10% Owner | 2026-04-22 | S | (11,982) | $0.30 | -$3,595 |
| 2026-04-23 | HRT FINANCIAL LP | 10% Owner | 2026-04-21 | P | 72,912 | $0.33 | $24,061 |
| 2025-12-19 | Brady Brian Michael | Director | 2025-12-17 | S | (1) | $1.75 | -$2 |
| 2025-11-26 | Pankovcin Corinne | Officer (Chief M&A Officer) | 2025-11-25 | S | (1) | $3.20 | -$3 |
| 2024-10-17 | HRT FINANCIAL LP | 10% Owner | 2024-10-16 | S | (25,534) | $1.17 | -$29,875 |
| 2024-10-17 | HRT FINANCIAL LP | 10% Owner | 2024-10-15 | P | 15,636 | $1.50 | $23,454 |